Skin irritation and potential efficacy of a novel compound for localized treatment of psoriasis

Gujjar1, J. Arbiser2, R. Coulon3, A. Banga11Mercer University College of Pharmacy, Department of Pharmaceutical Sciences, Atlanta, GA 303412Department of Dermatology, Emory University WinshipCancer Institute, Atlanta, GA 30322; Atlanta VA Medical Center, Decatur, GA 300333Accutis Pharmaceuticals, Inc., 4920 Pond Ridge Ln, Cumming, GA

Psoriasis is a chronic condition characterized by formation of white scaly patches on the skin. Current treatment options include topical glucocorticoids which have several side effects. Pentaerythritol tetrakis (3,5-di-tert-butyl-4-hydroxyhydrocinnamate) (PTTC) is a cinnamate tetraester which may be used as a novel topical treatment for psoriasis with less side effects. The purpose of this study was to determine the skin irritation and potential efficacy of PTTC using in vitro cell culture models.


Skin irritation, psoriasis, IL-6, oil-in-water emulsion, SOR-300-FT, MTT, proteosome inhibitor

Materials Tested

Cinnamate tetraester, Pentaerythritol tetrakis, 3,5‐di‐tert‐butyl‐4‐hydroxyhydrocinnamate, oil-in-water emulsion, sodium dodecyl sulfate (5%)

Request a copy of this paper, click here.